Get started
Author

Sai D. Prasad

Observed names: B. S. Sai Prasad, Sai D. Prasad, Sai D Prasad, Sai Prasad
ORCID: 0000-0002-5546-3673
Observed ORCID: 0000-0002-5546-3673
OpenAlex ID: A5020313763
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
2021 · Raches Ella, Krishna Mohan Vadrevu, et al. · The Lancet Infectious Diseases · 426
PDF
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
2021 · Raches Ella, Siddarth Reddy, et al. · The Lancet · 387
PDF
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
2021 · Raches Ella, Siddharth Reddy, et al. · The Lancet Infectious Diseases · 380
PDF
Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial
2014 · Nita Bhandari, Temsunaro Rongsen-Chandola, et al. · The Lancet · 335
Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life
2014 · Nita Bhandari, Temsunaro Rongsen-Chandola, et al. · Vaccine · 107
PDF
Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
2021 · Pragya D. Yadav, Raches Ella, et al. · Nature Communications · 105
PDF
Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)
2023 · Chandramani Singh, Savita Verma, et al. · npj Vaccines · 98
PDF
Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
2021 · Brunda Ganneru, Harsh Jogdand, et al. · iScience · 94
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
2021 · Sreelekshmy Mohandas, Pragya D. Yadav, et al. · iScience · 71
Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply
2020 · Sonia Pagliusi, Stephen Jarrett, et al. · Vaccine · 60
PDF
The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs
2023 · Andrew Farlow, Els Torreele, et al. · Vaccines · 59
PDF
Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
2022 · Raju Sunagar, Sai D. Prasad, et al. · Frontiers in Immunology · 39
PDF
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study
2022 · Krishna Mohan Vadrevu, Siddharth Reddy, et al. · The Lancet Infectious Diseases · 38
PDF
ROTAVAC ® does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial
2017 · Temsunaro Rongsen Chandola, Sunita Taneja, et al. · Heliyon · 32
PDF
Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152
2020 · Brunda Ganneru, Harsh Jogdand, et al. · SSRN Electronic Journal · 30
Immunogenicity and protective efficacy of BBV152: a whole virion inactivated SARS CoV-2 vaccine in the Syrian hamster model
2020 · Sreelekshmy Mohandas, Pragya D Yadav, et al. · 10
PDF
COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective
2021 · Benoit Hayman, Rajinder Suri, et al. · Vaccine · 9
PDF
Development and preclinical testing of HNVAC, a cell culture-based H1N1 pandemic influenza vaccine from India
2014 · Nagendra R. Hegde, Deepak Kumar, et al. · Vaccine · 9
Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152: A Phase 1, Double-Blind, Randomised Control Trial
2020 · Raches Ella, Krishna Mohan Vadrevu, et al. · SSRN Electronic Journal · 8
Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC® liquid formulations (ROTAVAC 5C & 5D) and non-inferiority comparisons with licensed ROTAVAC® (frozen formulation) in healthy infants
2023 · Krishna Kumari P, Siddharth Reddy Chiteti, et al. · Human Vaccines & Immunotherapeutics · 5
PDF
Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting
2022 · Rajinder Kumar Suri, Benoit Hayman, et al. · Vaccine · 5
PDF
A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™
2025 · Krishna Mohan Vadrevu, Abhishek Chavan, et al. · Vaccine · 4
Evidence of Extended Thermo-Stability of Typhoid Polysaccharide Conjugate Vaccines
2021 · Fang Gao, Kay Lockyer, et al. · Microorganisms · 4
PDF
Patterns of central line infections in two bone marrow transplant units in India among children undergoing allogeneic transplant for thalassaemia
2018 · Sandeep, Geetha Priya, et al. · Pediatric Hematology Oncology Journal · 1
PDF
Use of Convalescent Plasma in COVID-19
2020 · Aditya Kumar Perumallapalli, Sai Prasad, et al.
Works count: 25
Citation count: 2,316
H-index: 15
I10-index: 16
Year
Topic
Type